Pain Management
USF Health studies suggest new opioid-receptor signaling step could guide development of safer painkillers
Reported by AI Image generated by AI Fact checked
Researchers at USF Health report evidence that an early step in mu opioid receptor signaling can run in reverse, and that certain experimental compounds can enhance morphine- and fentanyl-driven pain relief in lab tests without increasing respiratory suppression at very low doses. The findings, published Dec. 17 in Nature and Nature Communications, are framed as a blueprint for designing longer-lasting opioids with fewer risks, though the newly tested molecules are not considered clinical drug candidates.
Researchers at the University of Arizona have found that certain compounds from the cannabis plant can reduce chronic pain in preclinical tests. The terpenes worked in models of fibromyalgia and post-surgical pain without producing psychoactive effects.
Reported by AI
A comprehensive analysis of opioid medications for short-term pain has concluded that these drugs typically provide only modest and brief relief. The review, covering dozens of conditions, found that opioids often perform no better than placebos in many cases. Researchers from the University of Sydney led the effort and highlighted risks of side effects and dependence.